Inovio Pharmaceuticals INO Stock News

Inovio Pharmaceuticals Inc (NASDAQ: INO) is making a run for the top in the premarket hours this morning, following up on the tremendous gains seen in the stock yesterday. However, if you go digging for press releases or SEC filings, you’ll find nothing. In fact, the gains seem to have to do with third party notariety surrounding the company’s compelling work in the development of a COVID-19 vaccine. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

A Recent New York Post Article Sent INO Stock For The Top

The recent run in Inovio Pharmaceuticals stock price seems to be triggered by a New York Post article. The article outlined the fact that progress is being made in an effort to produce a viable vaccine for COVID-19.

In particular, the article outlined the company’s work in conjunction with the University of Pennsylvania’s research facility as well as the Wistar Institute. The vaccine was developed quickly after the Chinese government made the genome sequencing of COVID-19 public.

Now, testing has started. After designing the vaccine in just 3 hours, using its proprietary DNA-based medicines platform, the vaccine is already heading into clinical trials, the first key step toward approval in the United States.

In a statement, Dr. Kate Brocderick, SVP of R&D at INO, had the following to offer:

We immediately started testing the vaccine in the laboratory. And we’re quite confident about the results that we’ve seen. We treated three people last week. But getting our vaccine into human beings is a huge step. But we did that in 83 days, which certainly in my career is absolutely an unprecedented level of speed.

In some patients, it looks like people who had the disease but now recovered have kind of these sort of low antibody levels, but we don’t know if that’s a consistent result across everybody that’s contracted the virus so far. So, we need to learn more about how the virus affects people and how people are affected by that infection before we can see too much about how that impacts vaccine design.

What we don’t know is that they contract the virus for a second time, which obviously would be very unlucky, but possible. Or is it just that they haven’t fully recovered the first time around? So that’s really what we’re learning as we speak and as we move forward. And that’s what kind of makes treating this virus very difficult because there’s still so much we don’t understand about it.

Why This News Is So Exciting

The truth of the matter is that Inovio Pharmaceuticals isn’t the only company in the race to develop a viable vaccine. However, it seems to be further along than any of its competition.

At the end of the day, the rapid development of a vaccine is much needed in the medical community. We’re hearing talks about reopening economies, and in these talks, there’s always a voice saying that we cannot fully open until a vaccine is available.

Once a vaccine is developed, it’s going to be met with incredible demand. So, the fact that INO is leading the charge on the vaccine development side of the coin suggests that the company may be the one of, if not, the first to produce a vaccine, making INO stock one that’s hard to ignore.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.